Skip to content

Exploring how magnetic therapy can help reduce craving for Opioid

A study of add-on rTMS on craving in patients with opioid dependence - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/10/075126
Enrollment
48
Registered
2024-10-11
Start date
Unknown
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F112- Opioid dependence

Interventions

Intervention1: rTMS(Repetitive transcranial magnetic stimulation): Patient will receive rTMS at 100% of RMT. Patients receiving active rTMS will get 2 sessions at interval of 15 mins of intermittent t

Sponsors

King George Medical University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosis of opioid dependence as per International Classification of Diseases 11th Revision ICD 11 Complete abstinence from opioids for at least 5 days Clinical Opioid Withdrawal Scale COWS score of less than 5 Informed written consent from the patient

Exclusion criteria

Exclusion criteria: A current diagnosis of any other psychiatric disorder except nicotine dependence and personality disorders Any significant medical comorbidity requiring priority management Not eligible to receive rTMS according to TMS screening checklist Any patient who doesnt have the mental ability to comprehend the consent form

Design outcomes

Primary

MeasureTime frame
To compare the craving experienced by patients with opioid dependence receiving antagonist treatment with add-on rTMS with those receiving antagonist treatment alone.Timepoint: Baseline 1 week 2 week 4 week

Secondary

MeasureTime frame
To compare the opioid use rates among patients with opioid dependence receiving antagonist treatment with add-on rTMS with those receiving antagonist treatment alone.Timepoint: Baseline 1 week 2 week 4 week;To compare the subjective well-being of patients with opioid dependance receiving antagonist treatment with add-on rTMS with those receiving antagonist treatment alone.Timepoint: Baseline 1 week 2 week 4 week

Countries

India

Contacts

Public ContactDr Sanjana Bhasin

King George Medical University

amitsingh0612@gmail.com8853817280

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026